Share Capital (Tables)
|
12 Months Ended |
Dec. 31, 2021 |
|---|
| Equity [Abstract] |
|
| Summary Of Warrants Activity |
The following table summarizes certain information in respect of the Company’s warrants:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Warrants outstanding, beginning |
|
|
49,236 |
|
|
$ |
4.06 |
|
|
|
49,236 |
|
|
$ |
4.06 |
|
| |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
|
|
(26,596 |
) |
|
|
3.84 |
|
|
|
— |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding, ending |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary Of Assumptions Used To Record Fair Value of Warrants |
As of December 31, 2021 and 2020, warrants classified as derivative liabilities on the consolidated balance sheets were revalued with the following inputs:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
0.9 |
% |
|
|
0.2 |
% |
| |
|
|
0.0 |
% |
|
|
0.0 |
% |
| |
|
|
93.7297.1 |
% |
|
|
148.0 –251.1 |
% |
| |
|
|
0.9 years |
|
|
|
0.9 years |
|
|
| Schedule Of Warrants Outstanding |
Full share equivalent warrants outstanding and exercisable are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
2021 |
|
|
For the Year Ended December 31,
2020 |
|
| |
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
|
|
|
|
Weighted Average
Exercise Price (C$) |
|
| |
|
|
— |
|
|
$ |
— |
|
|
|
26,596 |
|
|
$ |
4.37 |
|
| |
|
|
20,855 |
|
|
|
3.47 |
|
|
|
20,855 |
|
|
|
3.62 |
|
| |
|
|
1,785 |
|
|
|
4.57 |
|
|
|
1,785 |
|
|
|
4.57 |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Warrants outstanding |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Summary Of Potentially Dilutive Securities |
The following table summarizes potentially dilutive securities, and the resulting common share equivalents outstanding as of December 31, 2021 and 2020:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
10,504 |
|
|
|
11,510 |
|
| |
|
|
22,640 |
|
|
|
49,236 |
|
| |
|
|
46,458 |
|
|
|
46,458 |
|
| |
|
|
10,135 |
|
|
|
10,135 |
|
MPX dilutive instruments (1)
|
|
|
408 |
|
|
|
408 |
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
(1) |
Prior to the MPX Acquisition, MPX had instruments outstanding that were potentially dilutive and as a result of the MPX Acquisition, the Company assumed certain of these instruments. |
|
| Summary Of Option Activity |
The following table summarizes certain information in respect of option activity under the Company’s stock option plan:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For The Year Ended December 31, 2021 |
|
|
For The Year Ended December 31, 2020 |
|
|
|
|
|
|
Weighted
Average
Exercise
Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
|
|
|
|
Weighted
Average
Exercise
Price
(C$) |
|
|
Weighted
Average
Contractual
Life |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Options outstanding, beginning |
|
|
11,510 |
|
|
$ |
4.86 |
|
|
|
— |
|
|
|
19,578 |
|
|
$ |
4.80 |
|
|
|
— |
|
| |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
135 |
|
|
|
0.82 |
|
|
|
— |
|
| |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
| |
|
|
(1,006 |
) |
|
|
3.96 |
|
|
|
— |
|
|
|
(8,203 |
) |
|
|
4.99 |
|
|
|
— |
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Options outstanding, ending |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|